title: Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
abstract: The cellular proteasome is an important molecular target in cancer therapy and drug resistance research. Proteasome inhibitors are effective agents against multiple myeloma and mantle cell lymphoma and display great potential as treatment for a variety of other malignancies. The proteasome is a large multicatalytic, proteinase complex located in the cytosol and the nucleus of eukaryotic cells. The ubiquitin proteasome system is responsible for the degradation of most intracellular proteins and therefore plays an essential regulatory role in critical cellular processes including cell cycle progression, proliferation, differentiation, angiogenesis, and apoptosis. Cancer cells are particularly sensitive to proteasome inhibitors, indicating the utility for inhibition of the ubiquitin-proteasome pathway as an approach for cancer therapy.
authors.affiliation: Oakland University, School of Health Sciences, Biomedical Diagnostic and Therapeutic Sciences, Rochester, MI 48309, USA. landispi@oakland.edu
authors.forename: Kristin R
authors.initials: KR
authors.lastname: Landis-Piwowar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D061988:Proteasome Inhibitors; D025801:Ubiquitin / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D061988:Proteasome Inhibitors; D025801:Ubiquitin